MDM4 and CHEK1

Number of citations of the paper that reports this interaction (PubMedID 16163388)
126

Data Source:
BioGRID (enzymatic study, enzymatic study)
HPRD (in vitro)

		MDM4	CHEK1
Description		MDM4 regulator of p53	checkpoint kinase 1
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm	Chromosome, Telomeric Region Chromatin Condensed Nuclear Chromosome Extracellular Space Nucleus Nucleoplasm Replication Fork Cytoplasm Centrosome Cytosol Protein-containing Complex Intracellular Membrane-bounded Organelle
	Molecular Function	P53 Binding Protein Binding Zinc Ion Binding Enzyme Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity Protein Binding ATP Binding Protein Domain Specific Binding Histone Kinase Activity (H3-T11 Specific) Protein Serine Kinase Activity
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Heart Valve Development Atrioventricular Valve Morphogenesis Endocardial Cushion Morphogenesis Ventricular Septum Development Atrial Septum Development Regulation Of Transcription By RNA Polymerase II Negative Regulation Of Cell Population Proliferation DNA Damage Response, Signal Transduction By P53 Class Mediator Negative Regulation Of Protein Catabolic Process Negative Regulation Of Apoptotic Process Protein Stabilization Regulation Of Cell Cycle Protein-containing Complex Assembly Cellular Response To Hypoxia	DNA Damage Checkpoint Signaling G2/M Transition Of Mitotic Cell Cycle Inner Cell Mass Cell Proliferation DNA Replication DNA Repair Protein Phosphorylation Apoptotic Process Cellular Response To DNA Damage Stimulus DNA Damage Induced Protein Phosphorylation Nucleus Organization Mitotic G2 DNA Damage Checkpoint Signaling Regulation Of Double-strand Break Repair Via Homologous Recombination Regulation Of Transcription From RNA Polymerase II Promoter In Response To UV-induced DNA Damage Peptidyl-threonine Phosphorylation Histone H3-T11 Phosphorylation Intracellular Signal Transduction Regulation Of Cell Population Proliferation Mitotic G2/M Transition Checkpoint Positive Regulation Of Cell Cycle Negative Regulation Of Mitotic Nuclear Division Regulation Of Mitotic Centrosome Separation Chromatin-mediated Maintenance Of Transcription Negative Regulation Of G0 To G1 Transition Cellular Response To Mechanical Stimulus Replicative Senescence Regulation Of Signal Transduction By P53 Class Mediator Apoptotic Process Involved In Development Regulation Of Histone H3-K9 Acetylation
Pathways		Oxidative Stress Induced Senescence Oncogene Induced Senescence Ub-specific processing proteases Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation Stabilization of p53	Signaling by SCF-KIT Activation of ATR in response to replication stress Processing of DNA double-strand break ends Presynaptic phase of homologous DNA pairing and strand exchange TP53 Regulates Transcription of DNA Repair Genes Regulation of TP53 Activity through Phosphorylation G2/M DNA damage checkpoint Ubiquitin Mediated Degradation of Phosphorylated Cdc25A Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex Transcriptional Regulation by E2F6
Drugs			XL844 Enzastaurin CHIR-124 N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL 2-(cyclohexylamino)benzoic acid 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol 6-MORPHOLIN-4-YL-9H-PURINE 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE Fostamatinib
Diseases
GWAS		Breast cancer ( 23535733 27117709) Breast cancer (estrogen-receptor negative) ( 27117709 29058716) Breast cancer (estrogen-receptor negative, progesterone-receptor negative, and human epidermal growth factor-receptor negative) ( 24325915) Breast Cancer in BRCA1 mutation carriers ( 23544013) Cognitive performance ( 19734545) Diastolic blood pressure ( 27618452 30578418) Diastolic blood pressure (cigarette smoking interaction) ( 29455858) Diastolic blood pressure x alcohol consumption interaction (2df test) ( 29912962) Eosinophil counts ( 32888494) Eosinophil percentage of white cells ( 32888494) Fish- and plant-related diet ( 32066663) Glioma ( 28346443) Haemorrhoidal disease ( 33888516) Levodopa wearing off effect (time symptoms uncontrolled) in Parkinson's disease (response to zonisamide) ( 32355309) Non-glioblastoma glioma ( 28346443) Oily fish consumption ( 32066663) Pork consumption ( 32066663) Prostate cancer ( 23535732) Regular attendance at a religious group ( 29970889) Systolic blood pressure ( 27618452) Type 2 diabetes ( 32499647)	Breast cancer (survival) ( 25890600) Squamous cell lung carcinoma ( 28604730)
Interacting Genes		65 interacting genes: AKT1 APP ARF1 ATM BECN1 C1orf109 CAPN7 CASP3 CBLC CD160 CD44 CDK1 CDK4 CDKN2A CDKN2B CHEK1 CHEK2 CSNK1A1 E2F1 EP300 EPHA2 FGFR4 GLIS2 HGF LATS2 LRSAM1 MAGEA1 MAP2K5 MDM2 MKRN3 MNAT1 NAA10 NF2 PELI1 PRKAA1 RAD54B RB1 RNF115 S100B SFN SMAD3 SMAD4 SMARCA2 TOP2A TP53 TP63 TP73 TRIM46 TRIM55 UBC UBE2D1 UBE2D2 UBE2D3 USP7 VPS26C WDR5 YWHAB YWHAE YWHAG YWHAH YWHAQ YWHAZ ZCCHC2 ZKSCAN3 ZKSCAN4	54 interacting genes: AATF AKT1 APP ATM ATR ATXN3 BCL2L1 BLM BRCA1 BRCA2 CDC25A CDC25B CDC25C CHUK CLSPN CNTN2 CSNK2B CUL1 CUL4A DTL FANCE HSP90AA1 ILKAP LATS2 MAPT MCM6 MCM7 MCPH1 MDM4 NFRKB PDE2A PIGM PRKAA1 PRKDC RAD23A RAD51 RB1 RELA SMAD4 TIMELESS TLK1 TOPBP1 TP53 TP53BP1 TRAF4 UBA1 UBA2 UBB UBE2T USP3 XIAP XPO1 XRCC6 YWHAG
Entrez ID		4194	1111
HPRD ID		04082	04356
Ensembl ID		ENSG00000198625	ENSG00000149554
Uniprot IDs		A0A087WTR9 A0A087WUE3 A0A087WZ58 O15151 Q59FS6 Q68DC0	B4DT73 E7EPP6 O14757
PDB IDs		2CR8 2MWY 2N06 2N0U 2N0W 2N14 2VJE 2VJF 2VYR 3DAB 3EQY 3FDO 3FE7 3FEA 3JZO 3JZP 3JZQ 3LBJ 3MQR 3U15 4RXZ 5MNJ 5UML 5VK1 6Q9Q 6Q9S 6Q9U 6Q9W 6Q9Y 7C3Q 7C3Y 7C44	1IA8 1NVQ 1NVR 1NVS 1ZLT 1ZYS 2AYP 2BR1 2BRB 2BRG 2BRH 2BRM 2BRN 2BRO 2C3J 2C3K 2C3L 2CGU 2CGV 2CGW 2CGX 2E9N 2E9O 2E9P 2E9U 2E9V 2GDO 2GHG 2HOG 2HXL 2HXQ 2HY0 2QHM 2QHN 2R0U 2WMQ 2WMR 2WMS 2WMT 2WMU 2WMV 2WMW 2WMX 2X8D 2X8E 2X8I 2XEY 2XEZ 2XF0 2YDI 2YDJ 2YDK 2YER 2YEX 2YM3 2YM4 2YM5 2YM6 2YM7 2YM8 2YWP 3F9N 3JVR 3JVS 3NLB 3OT3 3OT8 3PA3 3PA4 3PA5 3TKH 3TKI 3U9N 4FSM 4FSN 4FSQ 4FSR 4FST 4FSU 4FSW 4FSY 4FSZ 4FT0 4FT3 4FT5 4FT7 4FT9 4FTA 4FTC 4FTI 4FTJ 4FTK 4FTL 4FTM 4FTN 4FTO 4FTQ 4FTR 4FTT 4FTU 4GH2 4HYH 4HYI 4JIK 4QYE 4QYF 4QYG 4QYH 4RVK 4RVL 4RVM 5DLS 5F4N 5OOP 5OOR 5OOT 5OP2 5OP4 5OP5 5OP7 5OPB 5OPR 5OPS 5OPU 5OPV 5OQ5 5OQ6 5OQ7 5OQ8 5WI2 6FC8 6FCF 6FCK
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?